Livmarli (maralixibat)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- maralixibat
- Company
- FGK Representative Service GmbH
- Status
- Application withdrawn
- Therapeutic area
- Cholestasis, Intrahepatic
- Designations
- Orphan
- Application
- EMEA/H/C/005551
- ATC
- A05AX
- Official record
- www.ema.europa.eu
Indication
Treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Livmarli Authorised · Mirum Pharmaceuticals International B.V.
Follow Livmarli
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.